- Precision Eligible to Receive up to $227 Million in Upfront Economics and Milestone Payments for Azer-Cel in Addition to Double-Digit Royalties on Sales- Imugene to Assume Control of Precision’s Cell Therapy Infrastructure in Pursuit of Biologics License Application for Azer-Cel in LBCL Patients who Relapse Follow.
Imugene Ltd (ASX:IMU, OTC:IUGNF) is acquiring the exclusive worldwide rights to develop and commercialise the azer-cel allogeneic CD19 CAR T cell therapy.
Precision BioSciences (DTIL) Completes Strategic Transaction with Imugene for Azer-Cel in Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Precision BioSciences Inc (NASDAQ: DTIL) announced the completion of a strategic transaction with Imugene Limited for global rights to Azercabtagene Zapreleucel (azer-cel), Precision's lead allogeneic CAR T candidate,
Imugene gains global rights to Precision BioSciences’ most advanced program, an allogeneic cell therapy for advanced cases of blood cancer. Precision will now focus on in vivo gene editing therapies, some of which is partnered with Novartis and Eli Lilly.